AR102228A1 - Una formulación de metformina de liberación sostenida y un método de preparación de la misma - Google Patents
Una formulación de metformina de liberación sostenida y un método de preparación de la mismaInfo
- Publication number
- AR102228A1 AR102228A1 ARP150103271A ARP150103271A AR102228A1 AR 102228 A1 AR102228 A1 AR 102228A1 AR P150103271 A ARP150103271 A AR P150103271A AR P150103271 A ARP150103271 A AR P150103271A AR 102228 A1 AR102228 A1 AR 102228A1
- Authority
- AR
- Argentina
- Prior art keywords
- sustained release
- release formulation
- fatty acid
- cellulose
- group
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title abstract 6
- 239000012730 sustained-release form Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 title abstract 2
- 229960003105 metformin Drugs 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 3
- 239000000194 fatty acid Substances 0.000 abstract 3
- 229930195729 fatty acid Natural products 0.000 abstract 3
- 150000004665 fatty acids Chemical class 0.000 abstract 2
- 239000008187 granular material Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 abstract 1
- 241000416162 Astragalus gummifer Species 0.000 abstract 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 abstract 1
- 229920002907 Guar gum Polymers 0.000 abstract 1
- 229920000084 Gum arabic Polymers 0.000 abstract 1
- 244000043261 Hevea brasiliensis Species 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 229920001615 Tragacanth Polymers 0.000 abstract 1
- 235000010489 acacia gum Nutrition 0.000 abstract 1
- 239000000205 acacia gum Substances 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940072056 alginate Drugs 0.000 abstract 1
- 235000010443 alginic acid Nutrition 0.000 abstract 1
- 229920000615 alginic acid Polymers 0.000 abstract 1
- 235000010418 carrageenan Nutrition 0.000 abstract 1
- 239000000679 carrageenan Substances 0.000 abstract 1
- 229920001525 carrageenan Polymers 0.000 abstract 1
- 229940113118 carrageenan Drugs 0.000 abstract 1
- 229920002301 cellulose acetate Polymers 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- -1 fatty acid ester Chemical class 0.000 abstract 1
- 235000010417 guar gum Nutrition 0.000 abstract 1
- 239000000665 guar gum Substances 0.000 abstract 1
- 229960002154 guar gum Drugs 0.000 abstract 1
- 229920000591 gum Polymers 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 abstract 1
- 229920003052 natural elastomer Polymers 0.000 abstract 1
- 229920001194 natural rubber Polymers 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229940068984 polyvinyl alcohol Drugs 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920003109 sodium starch glycolate Polymers 0.000 abstract 1
- 229940079832 sodium starch glycolate Drugs 0.000 abstract 1
- 239000008109 sodium starch glycolate Substances 0.000 abstract 1
- 235000010487 tragacanth Nutrition 0.000 abstract 1
- 239000000196 tragacanth Substances 0.000 abstract 1
- 229940116362 tragacanth Drugs 0.000 abstract 1
- 235000010493 xanthan gum Nutrition 0.000 abstract 1
- 239000000230 xanthan gum Substances 0.000 abstract 1
- 229920001285 xanthan gum Polymers 0.000 abstract 1
- 229940082509 xanthan gum Drugs 0.000 abstract 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Una formulación de liberación sostenida que comprende: un material granulado de libración sostenida, que contiene gránulos que comprenden metformina o una sal aceptable para uso farmacéutico de la misma y un polímero hinchable y una capa de recubrimiento que contiene un polímero insoluble en agua aplicada sobre la superficie de gránulos; y un superdesintegrante. Reivindicación 3: La formulación de liberación sostenida de la reivindicación 1, en la cual el polímero hinchable es al menos uno seleccionado del grupo que consiste en hipromelosa, hidroxietil celulosa, hidroxipropil celulosa, óxido de polietileno, carrageenan, goma natural, goma guar, tragacanto, goma de acacia, goma garrofín, goma de xantano, alginato, alcohol polivinílico y polivinilpirrolidona. Reivindicación 7: La formulación de liberación sostenida de la reivindicación 1, en la cual el polímero insoluble en agua es al menos uno seleccionado del grupo que consiste en copolímero de ácido metacrílico, etilcelulosa, acetato succinato de celulosa, acetato ftalato de celulosa, ácido graso, éster de ácido graso, alcohol de ácido graso y cera. Reivindicación 10: La formulación de liberación sostenida de la reivindicación 1, en la cual el superdesintegrante es al menos uno seleccionado del grupo que consiste en croscarmelosa sódica, almidón de sodio glicolato y crospovidona.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140137815A KR101642193B1 (ko) | 2014-10-13 | 2014-10-13 | 메트포르민 서방성 제제 및 그의 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR102228A1 true AR102228A1 (es) | 2017-02-15 |
Family
ID=55746869
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103271A AR102228A1 (es) | 2014-10-13 | 2015-10-09 | Una formulación de metformina de liberación sostenida y un método de preparación de la misma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20170304208A1 (es) |
| EP (1) | EP3207945B1 (es) |
| JP (1) | JP6449451B2 (es) |
| KR (1) | KR101642193B1 (es) |
| CN (1) | CN106659794A (es) |
| AR (1) | AR102228A1 (es) |
| AU (1) | AU2015331250B2 (es) |
| CA (1) | CA2952218C (es) |
| WO (1) | WO2016060365A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3053892A1 (fr) * | 2016-07-12 | 2018-01-19 | Urgo Recherche Innovation Et Developpement | Pansement permettant la liberation controlee et prolongee de la metformine |
| KR101910707B1 (ko) * | 2016-08-12 | 2018-10-22 | 충북대학교 산학협력단 | 복용순응도가 향상된 메트포르민 서방성 정제 및 이의 제조방법 |
| CN107184560B (zh) * | 2017-06-03 | 2021-02-02 | 寿光富康制药有限公司 | 二甲双胍胃滞留片及制备方法 |
| EP3721870A1 (de) | 2019-04-11 | 2020-10-14 | ADD Advanced Drug Delivery Technologies, Ltd. | Verfahren zur kontinuierlichen herstellung eines wirkstoffgranulats |
| CN113116842A (zh) * | 2019-12-31 | 2021-07-16 | 广州玻思韬控释药业有限公司 | 胃滞留片 |
| CN111346047B (zh) * | 2020-03-12 | 2022-04-01 | 复旦大学 | 一种热致水凝胶二甲双胍缓释制剂及其制备方法和应用 |
| PH12022552501A1 (en) * | 2020-05-29 | 2024-01-22 | Korea United Pharm Inc | Sustained-release metformin coated tablet having controlled release by osmotic pressure |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| US5007790A (en) * | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
| US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| JP2007507491A (ja) * | 2003-09-29 | 2007-03-29 | シージェー コーポレーション | 徐放性製剤 |
| WO2005084666A1 (en) * | 2004-03-02 | 2005-09-15 | Abeille Pharmaceuticals, Inc. | Co-formulations of kits of bioactive agents |
| TW200533391A (en) * | 2004-03-25 | 2005-10-16 | Sun Pharmaceutical Ind Ltd | Gastric retention drug delivery system |
| KR20060096728A (ko) * | 2005-03-02 | 2006-09-13 | 씨제이 주식회사 | 서방성 펠렛을 포함하는 서방성 제제 및 복합 서방성 정제 |
| KR100762847B1 (ko) * | 2006-01-27 | 2007-10-04 | 씨제이 주식회사 | 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법 |
| KR100791844B1 (ko) | 2006-06-30 | 2008-01-07 | 주식회사유한양행 | 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법 |
| JP2009191034A (ja) * | 2008-02-15 | 2009-08-27 | Ss Pharmaceut Co Ltd | 時限放出製剤 |
| KR101573889B1 (ko) * | 2009-10-09 | 2015-12-04 | 영진약품공업주식회사 | 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
| KR101597004B1 (ko) * | 2013-07-25 | 2016-02-23 | 씨제이헬스케어 주식회사 | 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제 |
-
2014
- 2014-10-13 KR KR1020140137815A patent/KR101642193B1/ko active IP Right Grant
-
2015
- 2015-07-21 WO PCT/KR2015/007526 patent/WO2016060365A1/ko active Application Filing
- 2015-07-21 CN CN201580044531.3A patent/CN106659794A/zh active Pending
- 2015-07-21 US US15/516,329 patent/US20170304208A1/en not_active Abandoned
- 2015-07-21 JP JP2017516836A patent/JP6449451B2/ja active Active
- 2015-07-21 CA CA2952218A patent/CA2952218C/en active Active
- 2015-07-21 AU AU2015331250A patent/AU2015331250B2/en active Active
- 2015-07-21 EP EP15850079.3A patent/EP3207945B1/en active Active
- 2015-10-09 AR ARP150103271A patent/AR102228A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2952218A1 (en) | 2016-04-21 |
| EP3207945B1 (en) | 2021-09-08 |
| JP6449451B2 (ja) | 2019-01-09 |
| CA2952218C (en) | 2019-04-16 |
| WO2016060365A1 (ko) | 2016-04-21 |
| CN106659794A (zh) | 2017-05-10 |
| KR101642193B1 (ko) | 2016-07-25 |
| JP2017529381A (ja) | 2017-10-05 |
| AU2015331250A1 (en) | 2017-01-12 |
| EP3207945A4 (en) | 2018-05-16 |
| EP3207945A1 (en) | 2017-08-23 |
| US20170304208A1 (en) | 2017-10-26 |
| AU2015331250B2 (en) | 2018-03-15 |
| KR20160043611A (ko) | 2016-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR102228A1 (es) | Una formulación de metformina de liberación sostenida y un método de preparación de la misma | |
| ES2655622T3 (es) | Una formulación de fármaco de liberación retardada | |
| JP2018090641A5 (es) | ||
| CY1126116T1 (el) | Φαρμακευτικες συνθεσεις αποτελουμενες απο νιλοτινιμπη | |
| TN2013000220A1 (en) | Orally disintegrating tablet | |
| PE20211976A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| AR104257A1 (es) | Tableta de ribociclib | |
| EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
| CL2013003331A1 (es) | Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz. | |
| AR103981A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención | |
| AR106166A1 (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
| CO6640256A2 (es) | Tableta enterica | |
| MX2018005456A (es) | Capsulas de liberación prolongada recubiertas con película. | |
| EP4074337A4 (en) | PHARMACEUTICAL FORMULATION OF TACI-FC FUSION PROTEIN | |
| UY37550A (es) | Nueva formulación que comprende un derivado de bencimidazol | |
| ES2623281T3 (es) | Composiciones farmacéuticas sólidas con recubrimiento entérico para inhibidores de la bomba de protones. | |
| AR071970A1 (es) | Composicion de liberacion pulsatil de sildenafil y proceso para prepararla | |
| AR092356A1 (es) | Formulacion compuesta para administracion oral que comprende metformina y rosuvastatina y metodo de preparacion de la formulacion | |
| RU2016150178A (ru) | Твёрдая дисперсия аллисартана изопроксила и фармацевтическая композиция | |
| BR112015023381A2 (pt) | composição de liberação imediata de sovaprevir, composição de sovaprevir de 200 mg, núcleo de comprimido de sovaprevir e comprimido de sovaprevir revestido | |
| JP2016516031A5 (es) | ||
| JP2019513801A5 (es) | ||
| AR097202A1 (es) | Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa | |
| ES2723029T3 (es) | Tableta entérica | |
| AR081935A1 (es) | Tableta con nucleo recubierto de liberacion controlada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |